Biogen Tysabri Facility Will Shift To Avastin Production Under New Owner
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.
You may also be interested in...
Genentech Manufacturing Deal With Lonza Provides For Future Biologic Expansion
Genentech plans to sell its 40,000-liter facility in Spain to Lonza, while in turn gaining the option to buy Lonza’s 80,000-liter facility in Singapore.
Genentech Manufacturing Deal With Lonza Provides For Future Biologic Expansion
Genentech plans to sell its 40,000-liter facility in Spain to Lonza, while in turn gaining the option to buy Lonza’s 80,000-liter facility in Singapore.
Biogen Idec To Reduce Annual Operating Expenses By $200 Mil.-$300 Mil.
Biogen Idec’s strategic plan calls for divesting the psoriasis biologic Amevive (alefacept) and 17% workforce reductions, or 650 employees.